CPRIT Awards 32 Grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Projects support product development, prevention and research advancements across Texas

The Cancer Prevention and Research Institute of Texas awarded 20 grants through its product development program, five grants through its prevention program and seven recruitment grants through its research program, totaling more than $65 million.

With a total requested amount of approximately $33.9 million, these early translational research grants awarded to Texas institutions include projects developing therapeutics, devices and new drugs.

The awarded research grants total approximately $24 million. The awarded prevention grants, totaling approximately $7.3 million, support prevention services for underserved populations in Texas. The projects receiving grants focus on increasing HPV vaccination rates and providing access to colorectal and cervical cancer screening. The project receiving a competitive continuation grant provides screening, training and educational services related to colon cancer.

The awarded product development grants for early translational research are:

  • Baylor College of Medicinethree grants totaling $5,927,789: Novel Separase Inhibitors to Treat Refractory Breast Cancer, $2,000,000; Oral Stat3 Inhibitor as Targeted Treatment for Triple-negative Breast Cancer, $1,999,569; and NKT Cell Platform for Cancer Immunotherapy, $1,928,220.
  • MD Anderson Cancer Centerthree grants totaling $5,045,493: Genetic Engineering of T Cells as an “Off-the-shelf” Therapy for Leukemias and Lymphomas, $1,992,245; Blood-based Markers for Screening and Early Detection of Colorectal Neoplasia, $1,693,599; and High-throughput Flow-proteometric System in Screening Functional Complexes as Cancer Biomarkers, $1,359,649.
  • The University of Texas at Austinthree grants totaling $4,949,450: Preclinical Development of a Therapeutic Enzyme for Immune Checkpoint Inhibition in Cancer, $1,790,486; Image-guided Smart Laser Knife for Cancer Surgery, $1,694,460; and Pre-IND Development of OxaliTex, $1,464,504.
  • The University of Texas Southwestern Medical Centerthree grants totaling $4,521,535: New Antibody Therapy for Treating Leukemia, $2,000,000; Targeting the SWI/SNF Chromatin-remodeling Complex in Liver Cirrhosis and Hepatocellular Carcinoma, $1,357,880; and Targeting the DC-HIL Receptor for Anti-cancer Immunotherapy, $1,163,655.
  • The University of Texas Health Science Center at San Antoniotwo grants totaling $3,990,904: Druggable Targets that Regulate the Antitumor Activity of ER-beta, $1,998,444; and ESR1 Coregulator Binding Site Inhibitors (ECBIs) as Novel Therapeutics to Target Hormone Therapy Resistant Metastatic Breast Cancer, $1,992,460.
  • The University of Texas Health Science Center at Houstontwo grants totaling $3,481,666: Targeting an Elusive Foe: Development of K-ras Inhibitors, $1,969,826; and Development of a Novel K-ras Therapeutic, $1,511,840.
  • Texas A&M University System Health Science CenterTherapeutic Targeting of Skp2/Ck1 to Restore Nuclear p27, $1,999,979.
  • The University of Texas Medical Branch at Galveston Inhibitors of Hydrogen Sulfide Biosynthesis: Preclinical Development of Novel Colorectal Cancer Therapies, $1,605,119.
  • Methodist Hospital Research InstituteImmunotherapy Targeting Triple Negative Breast Cancer Using NY-ESO-1-Specific TCRs and Blockade of Immune, $1,592,992.
  • University of North Texas Health Science Center at Fort WorthSelective Tumor Delivery of Anti-cancer Agents in Ovarian Cancer Therapy, $742,048.

The awarded prevention grants include funding for evidence-based cancer prevention services:

  • Texas Tech University Health Sciences Center: ACCION for Rural West Texas, $1,467,820.
  • Texas Tech University Health Sciences Center: Get FIT to Stay Fit. Stepping Up to Fight Colorectal Cancer in the Panhandle, $1,455,409.
  • MD Anderson Cancer Center: Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley Through Public Outreach, Patient Navigation and Telementoring, $1,441,085.
  • The University of Texas Medical Branch at Galveston: A Multi-pronged Approach to Increase HPV Vaccination Rates among Adolescents 9-17 years of Age from Galveston and Brazoria Counties, $1,406,919
  • And a competitive continuation/expansion grant for Texas A&M University System Health Science Center: Continuation and Expansion of Texas A&M’s Colon Cancer Screening, Training, Education and Prevention Program, $1,500,000.

Recruitment grants awarded indicate only approval to negotiate offers; at this time the candidates have not accepted offers. The research grants for recruitment were awarded to:

  • Robert Mattrey, for recruitment to The University of Texas Southwestern Medical Center from the University of California, San Diego, $6,000,000.
  • Samara Reck-Peterson, for recruitment to The University of Texas Southwestern Medical Center Department of Cell Biology from Harvard Medical School, $4,000,000.
  • Andres Leschziner, for recruitment to The University of Texas Southwestern Medical Center from Harvard University, $4,000,000.
  • Issam El Naqa, for recruitment to The University of Texas Southwestern Medical Center from McGill University Health Center, $4,000,000.
  • Xi Chen, for recruitment to Baylor College of Medicine from Weill Cornell Medical College, $2,000,000.
  • Marcin Imielinski, for recruitment to MD Anderson Cancer Center from Broad Institute of Harvard, $2,000,000.
  • Melanie Samuel, for recruitment to Baylor College of Medicine from Harvard University, $2,000,000.

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login